CA3183551A1 - Pyridine-1,5-diones exhibiting mnk inhibition and their method of use - Google Patents

Pyridine-1,5-diones exhibiting mnk inhibition and their method of use

Info

Publication number
CA3183551A1
CA3183551A1 CA3183551A CA3183551A CA3183551A1 CA 3183551 A1 CA3183551 A1 CA 3183551A1 CA 3183551 A CA3183551 A CA 3183551A CA 3183551 A CA3183551 A CA 3183551A CA 3183551 A1 CA3183551 A1 CA 3183551A1
Authority
CA
Canada
Prior art keywords
compound
alkyl
cycloalkyl
mmol
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3183551A
Other languages
English (en)
French (fr)
Inventor
Theodore J. Price
James J. SAHN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
4E Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3183551A1 publication Critical patent/CA3183551A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CA3183551A 2020-06-30 2021-06-30 Pyridine-1,5-diones exhibiting mnk inhibition and their method of use Pending CA3183551A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063046325P 2020-06-30 2020-06-30
US63/046,325 2020-06-30
PCT/US2021/039982 WO2022006331A2 (en) 2020-06-30 2021-06-30 Pyridine-1,5-diones exhibitng mnk inhibition and their method of use

Publications (1)

Publication Number Publication Date
CA3183551A1 true CA3183551A1 (en) 2022-01-06

Family

ID=79315594

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3183551A Pending CA3183551A1 (en) 2020-06-30 2021-06-30 Pyridine-1,5-diones exhibiting mnk inhibition and their method of use

Country Status (11)

Country Link
US (1) US20230286983A1 (cg-RX-API-DMAC7.html)
EP (1) EP4171565A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023533616A (cg-RX-API-DMAC7.html)
KR (1) KR20230041715A (cg-RX-API-DMAC7.html)
CN (1) CN116194112A (cg-RX-API-DMAC7.html)
AU (1) AU2021300363A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022026275A2 (cg-RX-API-DMAC7.html)
CA (1) CA3183551A1 (cg-RX-API-DMAC7.html)
IL (1) IL299512A (cg-RX-API-DMAC7.html)
MX (1) MX2022016516A (cg-RX-API-DMAC7.html)
WO (1) WO2022006331A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4363419A4 (en) * 2021-06-30 2025-06-11 4E Therapeutics, Inc. Spirocyclic pyridine-1,5-diones exhibiting mnk inhibition and their method of use
EP4646266A1 (en) * 2023-01-04 2025-11-12 4E Therapeutics, Inc. Solid state forms of mnk inhibitors
WO2026006417A1 (en) * 2024-06-26 2026-01-02 4E Therapeutics, Inc. Formulations of mnk inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012009735A (es) * 2010-02-26 2012-09-12 Boehringer Ingelheim Int 4-[cicloalquiloxi (hetero) arilamino] tieno [2,3-d] pirimidinas que tienen actividad inhibitoria de mnk1/mnk2 para composiciones farmaceuticas.
RU2014111055A (ru) * 2011-08-22 2015-09-27 Мерк Шарп И Доум Корп. 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
TWI713455B (zh) * 2014-06-25 2020-12-21 美商伊凡克特治療公司 MnK抑制劑及其相關方法
JP2018531266A (ja) * 2015-10-22 2018-10-25 セルビタ エス.エー. ピリドン誘導体およびキナーゼ阻害剤としてのその使用
CA3002558A1 (en) * 2015-10-29 2017-05-04 Effector Therapeutics, Inc. Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2
GB201520500D0 (en) * 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
JP2019510061A (ja) * 2016-03-31 2019-04-11 サウス オーストラリアン ヘルス アンド メディカル リサーチ インスティテュート リミテッドSouth Australian Health And Medical Research Institute Limited 高脂肪食関連疾患を阻害する方法
CA3064000A1 (en) * 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
EP3870178A4 (en) * 2018-10-24 2022-08-03 Effector Therapeutics Inc. Crystalline forms of mnk inhibitors
CN111484494B (zh) * 2019-01-29 2022-09-13 诺沃斯达药业(上海)有限公司 抑制mnk1和mnk2的多环化合物
EP3972593B1 (en) * 2019-05-23 2025-07-02 Board of Regents, The University of Texas System Inhibitor of mnk for the treatment of neuropathic pain
CN110256432A (zh) * 2019-06-27 2019-09-20 诺沃斯达药业有限公司 抑制mnk1和mnk2的多环化合物

Also Published As

Publication number Publication date
WO2022006331A9 (en) 2022-03-03
KR20230041715A (ko) 2023-03-24
MX2022016516A (es) 2023-03-28
WO2022006331A3 (en) 2022-02-10
JP2023533616A (ja) 2023-08-03
WO2022006331A8 (en) 2023-03-16
EP4171565A4 (en) 2024-11-27
US20230286983A1 (en) 2023-09-14
EP4171565A2 (en) 2023-05-03
CN116194112A (zh) 2023-05-30
WO2022006331A2 (en) 2022-01-06
BR112022026275A2 (pt) 2023-03-14
AU2021300363A1 (en) 2023-02-09
IL299512A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
US12110292B2 (en) Ligands to cereblon (CRBN)
US12398141B2 (en) JAK kinase inhibitor, preparation method for same, and applications thereof in field of medicine
US9314468B2 (en) Chemokine receptor modulators
US12030892B2 (en) CRBN modulators
US11766435B2 (en) N3-substituted iminopyrimidinones as antimalarial agents
US20250205244A1 (en) Methods of treating migraine with mnk inhibitors
AU2015402778B2 (en) Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
US20250186436A1 (en) Spirocyclic pyridine-1,5-diones exhibiting mnk inhibition and their method of use
US20230286983A1 (en) Pyridine-1,5-diones exhibiting mnk inhibition and their method of use
KR20230069984A (ko) Tyk2 억제제 및 그의 용도
US9975888B2 (en) Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
US20240400551A1 (en) Nek7 inhibitors
US20230118751A1 (en) Fused ring compound and application thereof
WO2022226182A1 (en) Nek7 inhibitors
TW202523670A (zh) Pde 7調節劑化合物

Legal Events

Date Code Title Description
P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241114

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250617

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250617

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250620

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250620

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250826

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250826

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250827

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260528

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260626

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260626